← All trials
NCT03796156
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 25, 2019
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 25210
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Moorgreen Hospital, SouthamptonLead sponsor
- Moorgreen Hospital, SouthamptonOverall official - principal investigator
- University of NottinghamCollaborator
- University of WarwickCollaborator
- University of DurhamCollaborator
- Epsom and St Helier University Hospitals NHS TrustCollaborator
- Epsom and St Helier University Hospitals NHS TrustOverall official - principal investigator
- East Kent Hospitals University NHS Foundation TrustCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.